Serum levels of microRNA-371-a-3p as a serum biomarker for early detection of relapses of testicular germ-cell tumours

Serum levels of microRNA-371-a-3p as a serum biomarker for early detection of relapses of testicular germ-cell tumours - microRNA follow-up study testis tumour

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00019223

Enrollment

250

Registered

2020-01-02

Start date

2019-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

testicular germ-cell tumour C62.9

Interventions

Group 1: Patients with testicular gem cell tumour stage 1 under surveillance (i.e. no adjuvant treatment) receive follow-up examinations according to current guide-lines recommendations. In addition t

Eligibility

Sex/Gender

Male

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: testicular germ cell tumour, clinical stage 1, no adjuvant therapy

Exclusion criteria

Exclusion criteria: clinical stage higher than stage 1

Design outcomes

Primary

Measure	Time frame
Early detection of tumour relapse: The goal is to determine the time interval between first elevation of microRNA 371 in serum and radiological detection of the relapse	—

Secondary

Measure	Time frame
A persistent elevation of serum microRNA-371a-3p levels does signify micrometastatic spread	—

Countries

Germany

Contacts

Public ContactKlaus-Peter Dieckmann

Asklepios Klinik Altona, Urologie, Hamburg

dieckmannkp@gmail.com040-181881 1661

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026